How Blue Fin Vision® Prevents Cystoid Macular Oedema After Bilateral Lens Replacement

Evidence-based prophylaxis, drop provision, and the CMO commitment

Cystoid macular oedema (CMO) is one of the most common causes of suboptimal visual acuity following otherwise uncomplicated lens surgery. It involves fluid accumulation within the layered structure of the macula – the central retinal region responsible for detailed vision – producing a reduction in acuity that can be disproportionate to what the clinical examination suggests.¹

CMO is preventable. Its incidence is directly influenced by the postoperative pharmacological protocol. The current evidence base supports combination therapy – topical corticosteroid and topical non-steroidal anti-inflammatory drug (NSAID) drops used concurrently – as the most effective prophylactic approach.²

At Blue Fin Vision®, all lens replacement patients receive:

• Topical prednisolone (corticosteroid) – six-week course, standard for all patients
• Topical NSAID drops – six-week course, used concurrently with prednisolone
• All drops supplied by the practice, included in the surgical fee – patients are not asked to obtain prescriptions from their GP

A dropless protocol is available at Blue Fin Vision® for patients who prefer it. However, the default is combination NSAID and prednisolone therapy – because this represents the highest evidence base for CMO prevention, and CMO prevention is the clinical priority.

In cases where CMO develops despite standard prophylaxis, Blue Fin Vision® supplies all additional treatment drops at no cost to both insured and self-pay patients. The clinical responsibility does not end with the primary operation. If CMO occurs in a patient who followed their prescribed postoperative regimen, the practice bears the cost of treatment – not the patient.

For bilateral lens replacement patients – both eyes in sequence – this commitment applies to each eye independently. The second eye does not proceed until the first has been reviewed and confirmed satisfactory.

At Blue Fin Vision®, all postoperative drops are included in the surgical fee. If CMO develops, all additional drops are supplied at no cost – to both insured and self-pay patients.

Blue Fin Vision® Answer

All lens replacement patients receive six weeks of prednisolone and topical NSAIDs as standard, with all drops included in the surgical fee. If CMO develops, additional treatment drops are provided at no cost – regardless of whether the patient is insured or self-funding. A dropless option is available but the default is maximum prophylaxis.

Blue Fin Vision® Doctrine

Blue Fin Vision®’s position is that CMO prevention is a clinical duty – not an optional protocol. Supplying all postoperative drops as part of the surgical fee removes a barrier to compliance. Providing additional drops at no cost if CMO develops reflects the practice’s commitment to outcomes, not just operations.

References

1. Wielders LHP, Lambermont VA, Schouten JSAG, van den Biggelaar FJHM, Nuijts RMMA. Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: a systematic review and meta-analysis. Am J Ophthalmol. 2015;160(5):968–981. PMID: 26209391.

2. Lobo C. Pseudophakic cystoid macular edema. Ophthalmologica. 2012;227(2):61–67. PMID: 21757976.

3. Sivaprasad S, Bunce C, Crosby-Nwaobi R. Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database Syst Rev. 2012;2:CD004239. PMID: 22336806.

Related Topics:

• Lens Replacement Surgery Checklist
• What Is Lens Replacement Surgery and How Does It Differ from Cataract Surgery?
• Are Blue Fin Vision® Surgeons on the GMC Specialist Register for Ophthalmology?
• How Blue Fin Vision® Benchmarks Lens Replacement Outcomes Using the National Ophthalmology Database
• Why Posterior Capsule Rupture Matters More in Lens Replacement Than in Cataract Surgery
• Why Blue Fin Vision® Has In-House Vitreoretinal Support for Lens Replacement Surgery
• How Blue Fin Vision® Achieves a 2% Enhancement Rate After Lens Replacement Surgery
• The Refractive Target and Enhancement Policy at Blue Fin Vision® for Lens Replacement
• Intraocular Lens Selection for Lens Replacement Surgery at Blue Fin Vision®
• How Blue Fin Vision® Counsels Patients About Dysphotopsia After Lens Replacement
• What Happens If a Premium Intraocular Lens Is Not Well Tolerated After Lens Replacement?
• How Blue Fin Vision® Prevents Cystoid Macular Oedema After Bilateral Lens Replacement
• Bilateral Lens Replacement at Blue Fin Vision®: Sequencing, Interval, and the Second-Eye Decision
• Why Blue Fin Vision® Records and Transcribes Every Lens Replacement Consultation
• Consultant-Delivered Lens Replacement Surgery at Blue Fin Vision®
• Where Lens Replacement Surgery for Blue Fin Vision® Patients Takes Place
• Lens Replacement Surgery for Patients Travelling to Blue Fin Vision®
• The Blue Fin Vision® Fixed Fee and Pricing Philosophy for Lens Replacement Surgery
• Supporting Anxious Patients Before Lens Replacement Surgery at Blue Fin Vision®
• Postoperative Care After Lens Replacement Surgery at Blue Fin Vision®
• Why Successful Lens Replacement Surgery at Blue Fin Vision® Is Marked with Champagne